近日,一项刊登在国际杂志《PNAS》上的研究报告显示,FDA批准的一种药物或能通过阻断新血管的生成来帮助有效抵御癌症。来自麻省总医院的研究人员表示,FDA批准的药物CXCR4抑制剂普乐沙福(AMD3100)够明显增强抗VEGF疗法的效用,同时还能够减缓抗VEGF疗法诱导的T细胞水平下降。在肿瘤微环境中,CXCR4主要会在单核细胞和中性粒细胞中进行表达,而且利用AMD3100阻断相应通路后就能够 Recently, a study published in the international magazine “PNAS” showed that a drug approved by the FDA could help fight cancer effectively by blocking the formation of new blood vessels. Researchers from the Massachusetts General Hospital said that the FDA-approved drug CXCR4 inhibitor, propylamine (AMD3100), significantly boosted the efficacy of anti-VEGF therapies while also slowing the decline in T-cell levels induced by anti-VEGF therapies. In the tumor microenvironment, CXCR4 is predominantly expressed in monocytes and neutrophils, and the ability to block the corresponding pathway using AMD3100